Stimunity
Develops STING-pathway drugs to stimulate immune responses against cancer and infectious diseases
Highlights
- New on EvolcAdded 2026-11-14
About Stimunity
Stimunity is a preclinical-stage biotechnology company developing drugs that activate the innate immune system through the STING pathway. Its technology is based on enveloped virus-like particles and academic research from Institut Curie, Inserm and the University of Oxford.
Its drug candidates are intended to help patients’ immune systems fight cancer and infectious pathogens. The company raised a €2 million seed investment from Portage Biotech and received funding through the EU Horizon 2020 programme.
Stimunity was founded in 2016 and is headquartered in Paris, France.
Product: Preclinical drug candidates and an enveloped virus-like particle platform that activates the STING pathway.
Jobs at Stimunity
More biotech & pharma companies
Strainchem
Green chemistry synthesis and process-development services for organizations working with small molecules and peptidesNew on EvolcSubstipharm
Develops and supplies medicines and vaccines for pharmaceutical partners and patients worldwideSuperbranche
Magnetic nanoparticles for focused-hyperthermia cancer treatment and imaging, developed for research and biotech partnersNew on EvolcSynaxys
Preclinical neuroscience assays and human neuronal models for pharmaceutical and research organizationsNew on EvolcSyndivia
Develops antibody-drug conjugate candidates and hinge-specific conjugation technology for cancer treatmentNew on EvolcSynthenova
Custom organic chemistry synthesis and R&D contracts for biotech, pharma, cosmetic and chemical companiesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Universal AnalyticsMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Hosting
- AWSHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-amz-cf-id
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.